SubsidieMeestersParagon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR)
Immunethep's PNV vaccine targets and blocks immunosuppressive GAPDH from five bacteria, enhancing immune response and showing high efficacy and safety in preclinical trials.
Projectdetails
Introduction
Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine).
Vaccine Overview
It protects against bacterial infections caused by 5 different bacteria:
- S. aureus
- S. pneumoniae
- K. pneumoniae
- E. coli
- GBS
Innovation
Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection.
Mechanism of Action
PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria.
Efficacy and Safety
Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the world’s first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 7.400.192 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 30-6-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- IMMUNETHEPpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniaeVAXDYN is developing innovative vaccines targeting antimicrobial-resistant infections, starting with K-VAX for Klebsiella pneumoniae, to combat a critical global health threat. | EIC Accelerator | € 2.494.748 | 2025 | Details |
A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHODeveloping a combination of meropenem and ANT3310 to combat drug-resistant Gram-negative infections, aiming for market approval by 2029 and projected sales over €10bn in 13 years. | EIC Accelerator | € 2.500.000 | 2023 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus NanoparticlesDiamante Società Benefit srl aims to develop a novel treatment for autoimmune diseases using virus nanoparticles to restore immune tolerance, reducing side effects compared to current therapies. | EIC Accelerator | € 2.499.999 | 2025 | Details |
Targeting Cancer with ERV VaccinesInProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Clinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniae
VAXDYN is developing innovative vaccines targeting antimicrobial-resistant infections, starting with K-VAX for Klebsiella pneumoniae, to combat a critical global health threat.
A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO
Developing a combination of meropenem and ANT3310 to combat drug-resistant Gram-negative infections, aiming for market approval by 2029 and projected sales over €10bn in 13 years.
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles
Diamante Società Benefit srl aims to develop a novel treatment for autoimmune diseases using virus nanoparticles to restore immune tolerance, reducing side effects compared to current therapies.
Targeting Cancer with ERV Vaccines
InProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered ProphagesPHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine. | ERC Starting... | € 1.500.000 | 2025 | Details |
InnomABsIPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie. | Mkb-innovati... | € 14.888 | 2023 | Details |
All-in-one supramolecular approach as an innovative anti-infectious strategyPATHO-LEGO aims to develop hybrid molecules that simultaneously block Pseudomonas aeruginosa adhesion and recruit natural antibodies to enhance immune clearance of resistant strains. | ERC Proof of... | € 150.000 | 2023 | Details |
Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phagesThis project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions. | ERC Starting... | € 1.499.250 | 2024 | Details |
NanoBiCar: A novel immunotherapy for infectious diseasesNanoBiCar aims to revolutionize bacterial infection treatment through innovative mRNA-based immunotherapy, targeting Mycobacterium tuberculosis to eliminate drug-resistant strains without generating resistance. | EIC Pathfinder | € 2.999.101 | 2025 | Details |
Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages
PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.
InnomABs
IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.
All-in-one supramolecular approach as an innovative anti-infectious strategy
PATHO-LEGO aims to develop hybrid molecules that simultaneously block Pseudomonas aeruginosa adhesion and recruit natural antibodies to enhance immune clearance of resistant strains.
Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phages
This project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions.
NanoBiCar: A novel immunotherapy for infectious diseases
NanoBiCar aims to revolutionize bacterial infection treatment through innovative mRNA-based immunotherapy, targeting Mycobacterium tuberculosis to eliminate drug-resistant strains without generating resistance.